Skip to main content
ANTX logo

ANTX · AN2 Therapeutics, Inc.

Track ANTX — free
$5.08 -0.14 (-2.68%) At close · Nov 20
Market Cap
$192.75M
Shares
37.94M
Volume · Nov 20 332.71K Avg daily vol (3M) 288.4K

Price & Indicators

 

Key stats

Close
$5.08
Fri 20 Nov
Open
$5.13
Fri 20 Nov
Average volume, 30 days
315K
shares a session
Short interest
2.4M
6.4% of shares · 9.2 days to cover
Day range
$4.99$5.49
Open $5.13 Close $5.08
52-week closing range
$1.03$6.28
Close $5.08 19.1% under the high
Short volume, last session
70%
Last earnings
May 19, 2026
Latest filing
10-Q · Nov 9
Price history
Mar 2022 to Nov 2026

Latest documents

2026
Nov 9
Investor event
PV trial plans December dosing, with updates through 2027

AN2 Therapeutics received FDA clearance for its polycythemia vera trial, plans to dose 10 patients in the sentinel cohort in December and expects milestone updates throughout 2027. The broader trial will enroll 75 patients, with initial data expected around May.

8 source passages
AN2 is a boron chemistry platform company, and we've discovered all of our molecules internally. So we have our polycythemia vera, and then we have two other ones, one for Chagas disease and one for non-tuberculous mycobacteria lung disease. Great. So let's start with PV. We just got regulatory clearance from the FDA we announced, as you mentioned earlier, and also simultaneously we announced we have Australia and India. The sentinel group is a low-dose run-in of 10 patients into a bigger part one, which is 75 total patients. So we're going to start in December. we're going to get started on this. We have, you know, kind of get the show on the road and with lots of kind of data and milestone updates throughout 2027. So we'll start hitting those kind of timelines around May for the initial patients. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash of $80.2 million supports current operating plan

AN2 Therapeutics had $80.2 million in cash and investments, expecting its current operating plan to fund operations for at least 12 months. Phase 2 startup was underway for epetraborole in polycythemia vera, while an investigator-initiated M. abscessus trial enrolled patients.

Net loss $7.96M Diluted EPS -$0.17
Read from the MD&A section
5 source passages
Except as otherwise indicated herein or as the context otherwise requires, references to “AN2,” “the Company,” “we,” “us” and “our” refer to AN2 Therapeutics, Inc. As of September 30, 2026, we had cash, cash equivalents, short-term and long-term investments of $80.2 million. Based on our current plan, we believe that our available cash will be sufficient to fund our operations for at least 12 months following the date of this Form 10-Q. Study startup activities are underway for a global Phase 2 study (EBO-PV-201) to evaluate the efficacy and safety of oral epetraborole in adults with phlebotomy-dependent PV. We are supporting an investigator-initiated trial (“IIT”) of oral epetraborole in M. abscessus lung disease and anticipate that data from this study, if positive, could provide clinical proof-of-concept in M. abscessus lung disease and thereby inform the design of a subsequent pivotal trial. Patient enrollment is ongoing. Open the document at this passage
Nov 9
Current report 8-K
Epetraborole PV trial cleared globally as net loss narrows

AN2 Therapeutics said the global Phase 2 study of oral epetraborole for polycythemia vera (PV) was cleared in all planned jurisdictions, with enrollment expected by year-end. Third-quarter net loss was $8.0 million, versus $9.4 million in 2025.

Financial results
3 source passages
Phase 2 global study of oral epetraborole in PV cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights. Net Loss: Net loss for the third quarter of 2026 was $8.0 million, compared to $9.4 million for the same period during 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$34.88M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$20.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+52.3%
Year over year · more shares
Price change (1Y)
+370.4%
Trailing year
Short interest
6.4%
Latest settlement · 9.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +18%
above
Price vs 50-day avg +13%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 77%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +43%
trailing
6-month return +25%
trailing
YTD return +346%
this year
Relative strength +34%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+33% holders QoQ · +24 funds added
Insider flow Distributing
Net -$1.8K over 90 days · 67% sells
Short interest Falling
6.43% of shares out · ▼ -15.5% MoM · 9.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
88 holders — near 3-yr high, broad support
Squeeze score 86
high risk · 0–100
Fundamentals
Excellent
EPS growth +33%
Y/Y
Balance sheet $19.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 135%
annualized · 1-yr
Max drawdown −46%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+18% Bullish
Price vs 50-day avg
+13% Bullish
RSI (14)
62 Neutral
MACD trend
Positive Bullish
52-week position
77% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+33% holders QoQ · +24 funds added
Insider flow Distributing
Net -$1.8K over 90 days · 67% sells
Short interest Falling
6.43% of shares out · ▼ -15.5% MoM · 9.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
88 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $5 · 77% Range high $6
vs 200-day avg +18% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and investments $80.2M as of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANTX
AN2 Therapeutics, Inc.
this stock
$192.75M +345.6% — — 6.4%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
88
% held
70.9%
Net QoQ
+2.3M sh
Top holder
Vivo Capital, LLC
Held Float
View
Held by Funds
Fund positions
76
View
Short & Settlement
Short Interest Falling
Shares short
2.4M
Days to cover
9.2d
Change
-447.3K sh
View
Short Volume
Short vol %
70%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
55.3K
Value
$250.1K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
33.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.8K
Buyers / Sellers
1 / 2
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-35.2M
EPS diluted
$-1.16
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
21

AN2 Therapeutics expects three phase 2 readouts next year and has $80 million in cash runway into 2029.

View
Proposed Sales
Value
$6.1M
Shares
1.0M
Filed
Aug 17, 2026
View
Exempt Offerings
Offering
$40.0M
Filed
Mar 25, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
AN2 Therapeutics to Present at Je…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ANTX +11.7% +43.1% +24.8% +12.1% +345.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +20.2% +52.3% +34.0% +20.9% +344.5%
Key facts CIK 1880438 CUSIP 037326105 13F (30d) 94 filings 85 filers Visit website Investor relations